Soleno Therapeutics, Inc. (SLNO)

52.73 -0.05 (-0.09%) USD  |  NASDAQ  |  Apr 20, 09:44
More

Soleno Therapeutics SG&A Expense (Quarterly) : 40.88M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for SLNO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Neurocrine Biosciences, Inc. 301.80M
Nektar Therapeutics 11.18M
Forian, Inc. 3.735M
Boston Scientific Corp. 1.834B
Integer Holdings Corp. 57.21M